Navigation Links
New Data Provide First Look at Ability to Detect Life-Threatening Heart Problems in Some High-Risk Patients

BALTIMORE, May 5, 2011 /PRNewswire/ -- New data presented today at the Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions are the first to look at the use of highly specialized signals within implantable cardioverter defibrillators (ICDs) to detect restricted blood flow to the heart in high-risk cardiovascular disease patients outside the hospital setting. Preliminary results from the ST-DETECT Trial using high-fidelity intracardiac electrogram (EGM) signals in ICDs show a low spontaneous coronary event rate (such as heart attack) among these patients.  

Using EGM signals to monitor and detect changes in the function of the heart has been studied in recent years, but these data are the first to examine the system specifically in patients with ICDs. ICDs are used in patients at risk for recurrent, sustained ventricular tachycardia or fibrillation, when the heart beats too quickly at a rate of more than 100 beats per minute. When an ICD detects ventricular tachycardia or fibrillation, it provides a painless shock to the heart to restore the normal rhythm and can potentially save the patient's life. The addition of the EGM signaling system has the potential to alert healthcare providers and the patients themselves if the patient is undergoing, or is about to undergo, a heart attack, allowing the patient optimal time to seek prompt treatment.

In the study, patients from 27 participating centers were monitored for 24 months following implantation of ICDs containing software for EGM. Patients qualified as high risk for a spontaneous coronary event (such as heart attack) by having one or more of the following risk factors:

  • A recent heart attack (six months or less)
  • A recent PCI (angioplasty) or stent
  • Multi-vessel disease, with one vessel more than 60 percent blocked, and/or
  • A recent positive stress test indicating heart disease

Additionally, the majority of patients were taking multiple medications, including antiplatelets (93 percent), cholesterol-lowering drugs (88 percent), blood pressure-lowering drugs (84 percent) and beta-blockers (93 percent).

Study results show a total of 182 adverse cardiovascular events in 89 of a total of 173 patients. A blinded, external endpoint committee reviewed the ischemia-related events, with the correlation between ischemia-related (blood flow to the heart) events and episodes of ST-segment deviations to be presented. The study was stopped early due to the low rate of heart attack among study participants.

"What's interesting about these data is there were virtually no heart events in this group of very sick patients, suggesting their disease was well managed by a combination of medical therapy and revascularization," said Timothy D. Henry, M.D., FSCAI, director of research and an interventional cardiologist at the Minneapolis Heart Institute at Abbott Northwestern Hospital. "Further research is needed to analyze the use of this signaling system within ICDs, as this innovation could open a new window to detecting heart attacks and preventing heart damage and death."

The ST-DETECT Trial was sponsored by Medtronic, Inc.

Dr. Henry will present "The ST-DETECT Trial" in the General Session on Thursday, May 5, 2011, 9:15 a.m. to 9:30 a.m.

About SCAI

Headquartered in Washington, D.C., the Society for Cardiovascular Angiography and Interventions is a 4,000-member professional organization representing invasive and interventional cardiologists in approximately 70 nations. SCAI's mission is to promote excellence in invasive and interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. SCAI's annual meeting has become the leading venue for education, discussion, and debate about the latest developments in this dynamic medical specialty. SCAI's patient and physician education program, Seconds Count, offers comprehensive information about cardiovascular disease. For more information about SCAI and Seconds Count, visit or

SOURCE Society for Cardiovascular Angiography and Interventions (SCAI)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. 900,000 Healthcare Providers Now Part of CAQH Universal Provider Datasource
2. Wolters Kluwer Health to Acquire Leading Global Drug Information Provider Lexi-Comp
3. Lexicon to Provide First Quarter 2011 Financial Results
4. Robotic Couch Provides Extra Degree of Precision for Patients Undergoing Radiation Therapy for Cancer
5. Cetero Research Seminars Provide Insights on Designing Accelerated Proof-of-Concept Studies
6. MedVantx and Blue Cross & Blue Shield of Rhode Island Partner to Provide Physicians with Integrated Medication Management Platform in Newly Created Patient-Centered Medical Homes
7. China Botanic Pharmaceutical Provides Update on Badger Oil Sales
8. Study Finds Letter to Health Care Providers Results in Reduction of Potentially Unsafe Concurrent Use of Plavix and Proton Pump Inhibitors
9. Thorne Research and Integrative Health Resources Establish Joint Venture to Provide Full Range of Services in Practice Development, Patient and Clinician Education, and Access to Nutritional Supplements in Integrative Medicine
10. Atrium Provides Grant to Establish Education Web Site at
11. Johnson & Johnson Provides Additional Information Regarding Amended Agreement With Merck
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015   Nottingham Spirk , ... announced the publication of a free whitepaper ... Medical Market". The whitepaper gives medical product companies, ... penetrating this lucrative segment. Nottingham Spirk ... to manage their own health, save money (i.e., ...
(Date:12/1/2015)... 2015 Array BioPharma Inc. (Nasdaq: ... Chief Executive Officer, Ron Squarer , ... Conference in New York.  The public is ... a webcast on the Array BioPharma website. ... --> , --> ...
(Date:12/1/2015)... , BANGALORE, India and ... N.V. (NASDAQ, TASE: MYL) today announced that it expects ... and for developing country markets funded by international donors, ... mg + Efavirenz 400 mg) for $99 per patient, ... Initiative (CHAI) to develop TLE400. The significantly reduced price ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... For the millions of ... Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic intermittent catheter. ... touch free catheter portfolio,” said Michael Gresavage, Vice President North America. "We designed ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... of Excellence (BHCOE) today announced that the organization has awarded Education and Developmental ... with a Distinguished Award. The award celebrates exceptional special needs providers that excel ...
(Date:12/1/2015)... ... 01, 2015 , ... McLean, VA., December 1, 2015 - ... per sprint agile development contract to support the National Geospatial-Intelligence Agency's (NGA) IT ... software engineering, infrastructure, as well as operations and sustainment support to the NGA’s ...
(Date:12/1/2015)... Auburn, CA (PRWEB) , ... December 01, 2015 ... ... software and clinical solutions for the care management and population health arenas, is ... on providing clinical and cost containment services, has successfully implemented the ACUITY Complete ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... has selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s ... including CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica ...
Breaking Medicine News(10 mins):